Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
Strategic collaboration announced with Sobi for global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan Marketing authorization application (MAA) validated by EMA for pegcetacoplan in PNH. New drug application (NDA) …